I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Carboplatin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms I-CURE-1
- 31 Aug 2018 Biomarkers information updated
- 25 Jul 2018 Status changed from recruiting to suspended.
- 28 Sep 2017 Status changed from not yet recruiting to recruiting.